Overview

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Status:
Completed

Trial end date:
2019-01-21

Target enrollment:

Participant gender:

Summary

Patients with metastatic breast cancer considered HER2 negative are screened for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor cell is detected, patients are treated by Trastuzumab - Emtansine (T-DM1) in a single arm phase II with an adaptive design.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Curie

Treatments:

Ado-trastuzumab emtansine
Maytansine
Trastuzumab